Ovarian Cancer Individualized Scoring System Scoring System
OCISS
1 other identifier
observational
1,000
1 country
2
Brief Summary
This project aims at creating an individualized prognostic model using patient characteristics and disease features to determine disease prognosis using machine learning technology. The model can be used to determine the optimal management plan per patient in priori and highlight risk and timing of disease recurrence.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2022
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2022
CompletedFirst Posted
Study publicly available on registry
August 11, 2022
CompletedStudy Start
First participant enrolled
November 11, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 11, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 22, 2023
CompletedAugust 11, 2022
August 1, 2022
9 months
August 9, 2022
August 9, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Cancer-specific survival (CSS) rate at 5 years
Percentage of women newly diagnosed with ovarian cancer who do not die from ovarian cancer after 5 years
Within 5 years after diagnosis of ovarian cancer
Cancer-specific survival (CSS) rate at 3 years
Percentage of women newly diagnosed with ovarian cancer who do not die from ovarian cancer after 3 years
Within 3 years after diagnosis of ovarian cancer
Secondary Outcomes (2)
Recurrence-free survival (RFS) rate at 5 years
Within 5 years of diagnosis of ovarian cancer
Recurrence-free survival (RFS) rate at 3 years
Within 3 years of diagnosis of ovarian cancer
Eligibility Criteria
All women who will be diagnosed with primary ovarian cancer at any stage, of all histological types and grades eligible for the study
You may qualify if:
- Women diagnosed with ovarian cancer between January 2010 and December 2016.
- Primary non-recurrent diagnosis of ovarian cancer.
- Women should be diagnosed and managed by the corresponding center.
- Patients with adequate clinical and pathological data
You may not qualify if:
- Inadequate information and follow-up for at least 5 years.
- Authorization to use anonymous patient data for research purposes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Alexandria University Main Hospital
Alexandria, 21516, Egypt
Assiut Hospitals university
Asyut, 71511, Egypt
Related Publications (10)
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
PMID: 33538338BACKGROUNDCaan BJ, Thomson CA. Breast and ovarian cancer. Optim Women's Heal through Nutr. Published online 2007:229-263. doi:10.1369/0022155411428469
BACKGROUNDUrban N. Early detection of ovarian cancer: Methodological considerations. Int J Gynecol Obstet. 2000;70:D9-D9. doi:10.1016/s0020-7292(00)82512-6
BACKGROUNDJacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004 Apr;3(4):355-66. doi: 10.1074/mcp.R400006-MCP200. Epub 2004 Feb 5.
PMID: 14764655BACKGROUNDGoff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004 Jun 9;291(22):2705-12. doi: 10.1001/jama.291.22.2705.
PMID: 15187051BACKGROUNDJordan SJ, Green AC, Whiteman DC, Webb PM; Australian Ovarian Cancer Study Group. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol. 2007 Nov;107(2):223-30. doi: 10.1016/j.ygyno.2007.06.006. Epub 2007 Jul 27.
PMID: 17662378BACKGROUNDMomenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30;11:287-299. doi: 10.2147/IJWH.S197604. eCollection 2019.
PMID: 31118829BACKGROUNDSalvo G, Odetto D, Pareja R, Frumovitz M, Ramirez PT. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. Int J Gynecol Cancer. 2020 Jun;30(6):873-878. doi: 10.1136/ijgc-2020-001257. Epub 2020 Apr 1.
PMID: 32241876BACKGROUNDWright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI, Hershman DL. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019 Jul;134(1):49-57. doi: 10.1097/AOG.0000000000003311.
PMID: 31188324BACKGROUNDMcCorkle R, Pasacreta J, Tang ST. The silent killer: psychological issues in ovarian cancer. Holist Nurs Pract. 2003 Nov-Dec;17(6):300-8. doi: 10.1097/00004650-200311000-00005.
PMID: 14650572BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant lecturer
Study Record Dates
First Submitted
August 9, 2022
First Posted
August 11, 2022
Study Start
November 11, 2022
Primary Completion
August 11, 2023
Study Completion
November 22, 2023
Last Updated
August 11, 2022
Record last verified: 2022-08